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Abstract The accumulation of excess glutamate in the ex-
tracellular space as a consequence of CNS trauma, neuro-
degenerative diseases, infection, or deregulation of
glutamate clearance results in neuronal damage by excessive
excitatory neurotransmission. Glutamate excitotoxicity is
thought to be one of several mechanisms by which HIV
exerts neurotoxicity that culminates in HIV-associated
neurocognitive disorders (HAND). Excess glutamate is re-
leased upon HIV infection of macrophage/microglial cells
and has been associated with neurotoxicity mediated by
gp120, transactivator of transcription (Tat) and other HIV
proteins. Several strategies have been used over the years to
try to prevent glutamate excitotoxicity. Since the main toxic
effects of excess glutamate are thought to be due to
excitotoxicity from over activation of glutamate receptors,
antagonists of these receptors have been popular therapeutic
targets. Early work to ameliorate the effects of excess
extracellular glutamate focused on NMDA receptor antago-
nism, but unfortunately, potent blockade of this receptor has
been fraught with side effects. One alternative to direct
receptor blockade has been the inhibition of enzymes re-
sponsible for the production of glutamate such as glutamin-
ase and glutamate carboxypeptidase II. Another approach
has been to regulate the transporters responsible for modu-
lation of extracellular glutamate such as excitatory amino
acid transporters and the glutamate-cystine antiporter. There
is preliminary experimental evidence that these approaches
have potential therapeutic utility for the treatment of HAND.
These efforts however, are at an early stage where the next
steps are dependent on the identification of drug-like in-
hibitors as well as the development of predictive neuroAIDS
animal models.
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Introduction
The introduction of combination antiretroviral therapy
(cART) in 1996 brought a dramatic reduction in HIV RNA
levels and thus morbidity and mortality rates in human
immunodeficiency virus (HIV) infected individuals (Coiras
et al. 2009). Although cART has been successful, it has not
eradicated the disease as the virus can persist in resting
memory CD4+ T cells as well as macrophages and astro-
cytes (Coiras et al. 2009). These latent reservoirs of HIV are
easily and quickly activated if cessation of cART treatment
occurs (Lewin et al. 2008). Elimination of these reservoirs is
a major goal of current research in the HIV field. Even with
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continuous cART therapy, significant morbidity persists, in
particular in the central nervous system (CNS) (Gorantla et
al. 2012) where memory problems and dementia are com-
mon. It is thought that HIV-associated neurocognitive dis-
orders (HAND) remain high due to both latent reservoir and
reduced penetrance of cART to the brain.
HIV initially enters the brain by crossing the blood
brain barrier via monocytes and lymphocytes very short-
ly after infection (Fig. 1). The virus then takes up
permanent brain residence mainly in microglia, macro-
phages and astrocytes (Kaul et al. 2001; Tan and
McArthur 2012). HIV does not infect neurons, though
neural progenitor cells appear able to take up the virus
(Kaul 2008). Neurotoxicity in patients with HIV-1 in-
fection is thought to be mediated by HIV-1 proteins
such as gp120 and transactivator of transcription (Tat),
as well as other products released from infected cells.
The mechanisms of neurotoxicity are thought to be both
direct and indirect including glutamate excitotoxicity,
oxidative stress, increase in apoptosis, altered calcium
homeostasis, stimulation of tumor necrosis factor-alpha
(TNF-α) and nuclear factor κB (NF-kB) and stimulation
of nitric oxide production. These mechanisms are likely
acting in concert.
Although multiple mechanisms are at play, the objective
of this review is to present the evidence which indicates that
glutamate excitotoxicity is a factor in HIV neurotoxicity and
to focus on how this evidence suggests potential opportuni-
ties to ameliorate HAND through pharmacological manipu-
lations of the glutamate system.
Mechanisms of glutamate excitotoxicity in HAND
The amino acid glutamate is the principal excitatory
neurotransmitter in mammalian CNS where it is synthe-
sized and stored in the neuronal cytosol in synaptic
vesicles in millimolar concentrations (Nedergaard et al.
2002). Extracellular concentrations of glutamate in the
synaptic cleft are kept low (nanomolar ranges) by ex-
citatory amino acid transporters (EAATs). These are
glutamate transporters which are located mainly on as-
trocytes and function in removing excess glutamate
from the synaptic cleft after the completion of a signal-
ing event, returning it to homeostatic levels.
The accumulation of excess glutamate in the extracellular
space as a consequence of CNS trauma, neurodegenerative
diseases, infection, or deregulation of glutamate clearance
results in excitotoxicity. The presence of excess glutamate in
the synaptic clefts activates glutamate gated ion channels
and results in high levels of ion influx into neuronal cells
allowing the over activation of downstream calcium ion-
dependent effectors and signaling pathways, culminating in
neuronal damage. Neuronal damage then causes further
release of intracellular glutamate into the extracellular space
affecting nearby neurons. Most acute and chronic neuronal
diseases, including HAND, have implicated this type of
bystander pathology of excitotoxicity.
HIV infection of macrophages and microglial cells causes
excess glutamate release and impaired uptake
Macrophages and microglia, the resident macrophages in
the CNS, are key cellular components of innate immu-
nity. These cells can release a diversity of trophic fac-
tors and cytokines that control the behavior and/or
destiny of other cells by promoting cell proliferation,
migration, recruitment, and apoptosis. Additionally,
macrophages and microglial cells play an important role
in the phagocytosis of invading pathogens, tissue repair
and the clearance of debris (Liu and Hong 2003). The
activity of these cells is highly regulated both spatially
and temporally due to the potential deleterious effects of
their uncontrolled hyperactivation, which include in-
crease in inflammation and cell death. Microglial cells
are particularly susceptible to alterations in their sur-
roundings, becoming easily activated, changing mor-
phology and up-regulating the production of a number
of membrane receptors and soluble factors (Kreutzberg
1996; Ransohoff and Perry 2009). Conditions that in-
volve neuronal degeneration like HAND, Alzheimer’s
disease, cerebral ischemia and multiple sclerosis, have
been associated with microglial cells pathological activ-
ity (Gao and Hong 2008; Zindler and Zipp 2010).
Invasion of the brain seems to occur very early in the
progression of the disease. However, there is no convincing
evidence of HIV-1 neuronal infection despite the fact that
HIV-1 associated neuronal dysfunction is accompanied by
substantial neuronal loss in the neocortex, putamen, globus
pallidus, substantia nigra and hippocampus (Everall et al.
1991; Masliah et al. 1992). Hence it is widely accepted that
macrophages and microglial cells are responsible for pro-
ducing and releasing the neurotoxic factors that cause neu-
ronal death (Gendelman 2012). HIV-1 is capable of
infecting CD4+ macrophages and T-cells (Chen et al.
1983; Popovic et al. 1983; Klatzmann et al. 1984a, b).
Infected macrophages are thought to cross the blood–brain
barrier (BBB), turn into resident CNS macrophages and
mediate the spread of the virus in the brain (Fig. 1). There
is considerable evidence that supports this hypothesis
(“Trojan horse” hypothesis) as the mechanism of brain
infection by HIV-1 (Peluso et al. 1985; Budka 1986,
1991; Koenig et al. 1986; Kure et al. 1990; Dickson et
al. 1993; Fischer-Smith et al. 2001). Upon activation,
HIV-1 infected macrophages and microglial cells release
chemokines, inflammatory cytokines (TNF-α, IL-1β, IL-
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6), nitric oxide (NO) and glutamate. Excess glutamate
can induce neuronal damage through N-methyl-D-aspar-
tate (NMDA) receptor activation (Cutler and Dudzinski
1974; Fonnum 1984). Indeed, HIV-1 infected patients
show elevated CSF glutamate levels that correlate with
the severity of the dementia and the degree of brain
atrophy (Ferrarese et al. 2001).
Several glutamate targets (Fig. 2) have been shown to
be affected by HIV infection. HIV-1 infected human
macrophages and human primary fetal microglia cells
have increased glutaminase mRNA and protein levels
resulting in elevated extracellular glutamate levels that
cause reduced viability of cortical neurons in co-culture
or of neurons incubated with conditioned media from
these infected cells (Tian et al. 2008; Erdmann et al.
2009; Huang et al. 2011; Zhao et al. 2012). MK-801
(dizocilpine) a non-competitive antagonist at the NMDA
receptor abolished the effects on neuronal viability,
suggesting this is an NMDA receptor-dependent process
(Wong et al. 1986).
Treatment of macrophages and microglial cells with pro-
inflammatory factors like lipopolysaccharides (LPS) or
HIV-1 Tat protein generates reactive oxygen species
(ROS), which seem to contribute to the accumulation of
Fig. 1 Mechanisms of glutamate excitoxicity during HIV-1 infection
(1) Infection of circulating monocytes with HIV-1. (2) HIV-1 infected
macrophages cross the BBB and become perivascular macrophages.
(3) HIV-1 infected perivascular macrophages in the brain parenchyma
release viral particles that infect other brain macrophages and
microglial cells. (4) Activated macrophages and microglial cells release
viral proteins gp120 and Tat, glutamate and other factors such as NO,
ROS, cytokines, chemokines and arachidonic acid that can either
directly or indirectly affect glutamate metabolism and/or transport.
(5) Decrease in glutamate uptake by oligodendrocytes and astrocytes
due to increased levels of these toxins released by HIV-1 infected
macrophages and microglial cells. These factors also cause an increase
in vesicular glutamate release by astrocytes. (6) Viral proteins Tat and
gp120 and oxidative stress induced by ROS and NO cause an increase
in the activity of xCT in uninfected perivascular macrophages and
microglia and as a consequence extracellular levels of glutamate in-
crease. (7) Excessive extracellular glutamate triggers activation of
glutamate receptors on neurons causing an increase in the intracellular
calcium levels, cell death and neuronal degeneration
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extracellular glutamate and neuronal cell death in a process
involving the glutamate-cystine antiporter (xCT) (Barger et
al. 2007; Niki 2009).
It has been shown that up to 19 % of astrocytes in the
brain of patients with HAND are infected with HIV-1 and
that there is a direct correlation between the level of infected
astrocytes and the degree of neuropathological changes
(Churchill et al. 2009). Unlike macrophages and microglia,
astrocytes are latently infected by HIV-1 making these cells
incapable of releasing viral particles. Nonetheless, HIV-1
mRNAs (Tat, Rev and Ref) and proteins (Nef) accumulate
inside astrocytes affecting their function (Sabri et al. 2003).
Changes induced in astrocytes by HIV infection include
activation, production and release of inflammatory cyto-
kines and chemokines, and glutamate release (Fig. 1)
(Benveniste 1998; Bajetto et al. 2002; John et al. 2003;
Eugenin and Berman 2007; Farina et al. 2007).
Cytokines such as TNF-α and IL-1β released by activat-
ed microglia, macrophages or astrocytes treated with viral
proteins like gp120 or Tat cause increased glutamate release
and decreased extracellular glutamate uptake by astrocytes
due to down regulation of EAAT1 and EAAT2 gene expres-
sion (Wang et al. 2004; Lee et al. 2005; Brabers and Nottet
2006; Cheung et al. 2008).
Fig. 2 Potential ways to regulate glutamate excitotoxicity for the
treatment of HAND (1) Inhibition of glutaminase - glutaminase is a
neuronal enzyme that produces glutamate by the deamination of glu-
tamine. During HIV-1 infection, it is increased in glial cells and the
synaptic cleft. (2) Inhibition of GCPII - GCPII is an astrocytic enzyme
that catalyzes the hydrolysis of NAAG to N-acetyl aspartate (NAA)
and glutamate. (3) Blockade of glutamate receptors- glutamate recep-
tors such as NMDA, AMPA, kainate and mGluR are targets for
inhibition of glutamate excitotoxicity in HAND. (4) Inhibition of
xCT - xCT transports extracellular cys2 into cells and intracellular
glutamate into the extracellular space. (5) Activation of glutamate
transporters (e.g. EAAT1) – glutamate transporters mobilize glutamate
away from the synaptic cleft. Glutamate and NAAG are released through
intracellular vesicles at the presynaptic terminal during neurotransmis-
sion. The illustration shows NAAG and glutamate in the same vesicles
but it is not known if they are in the same or different vesicles
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Moreover, excess extracellular glutamate can induce ele-
vation of intracellular calcium levels in astrocytes which in
turn increases even more the release of glutamate from those
cells in an autocrine manner (Verderio et al. 2001; Verderio
and Matteoli 2001). Calcium influx in astrocytes may de-
crease EAAT1 levels in these cells by a CD38-dependent
mechanism contributing to the accumulation of extracellular
glutamate (Bruzzone et al. 2004; Liu et al. 2010). In short, a
major contributor to the neuronal toxicity due to glutamate
in HAND seems to be the aberrant glutamate transport
and/or metabolism in astrocytes caused by viral toxins,
cytokines or glutamate.
Glutamate toxicity in HIV-1 infected patients could also
depend on altered glutamate transport in oligodendrocytes
(Domercq et al. 2007). Co-culture of LPS-activated microg-
lia and oligodendrocytes or incubation of oligodendrocytes
with conditioned media from LPS-activated microglia
inhibited glutamate uptake by oligodendrocytes resulting
in extracellular glutamate accumulation and cell death (Pang
et al. 2010). Moreover, peroxynitrite, the product of the
reaction between superoxide and NO, is a potent inhibitor
of EAAT glutamate transporters GLAST, GLT-1 and
EAAC1 (Trotti et al. 1996). Taken together, compromised
clearance of extracellular glutamate from the synaptic cleft
by oligondendrocytes, allows levels of glutamate to increase
and cause toxicity in neurons.
GP120 neurotoxicity and glutamate
Gp120 is the main HIV envelope glycoprotein that, along
with gp41, allows the entry of HIV-1 into cells via the CD4
receptor along with CCR5 and CXCR4 receptors. The ami-
no acid sequence of this protein consists of five variable
regions (V1-V5) and five constant domains (C1-C5)
(Checkley et al. 2011). There is both in vitro and in vivo
evidence indicating that gp120 triggers neurotoxicity (Doble
1999). Gp120 is toxic to cultured rat hippocampal neurons
in vitro (Brenneman et al. 1988; Dreyer and Lipton 1995),
produces cognitive deficits in rats (Glowa et al. 1992) and
causes impaired neuronal development in rat neonates (Hill
et al. 1993; Bagetta et al. 1994). Further, transgenic mice
expressing gp120 in astrocytes develop neurodegeneration
(Toggas et al. 1994). Gp120 neurotoxicity is thought to
contribute to cortical atrophy (Lipton 1992a), a condition
associated with cognitive impairment observed in some
AIDS patients (Power and Johnson 1995).
NMDA receptor antagonists, but not CNQX, an
AMPA receptor antagonist, prevent in vitro gp120 neu-
rotoxicity in rodent cultures suggesting that gp120 neu-
rotoxicity is mediated, at least in part, by the NMDA
receptor (Lipton et al. 1991; Lipton 1992a, b; Muller et
al. 1992; Savio and Levi 1993). Interestingly, if glutamate
is removed enzymatically from the cell culture milieu, gp120
excitotoxicity is lost (Lipton et al. 1991). Furthermore,
neurodegeneration in gp120-expressing transgenic mice can
be ameliorated by the NMDA antagonist memantine (Toggas
et al. 1996) and the glutamate release inhibitor riluzole
(Sindou et al. 1994).
Gp120 is also known to trigger NMDA receptor-
mediated cell death in human neurons (Corasaniti et al.
1995; Lannuzel et al. 1995; Wu et al. 1996). However,
gp120 receptors (CD4 receptors) are not found in neurons
so that gp120 neurotoxicity mediated by NMDA receptors is
likely through an indirect mechanism (Lipton et al. 1991)
involving glutamate release from infected macrophage and
microglia. Macrophages are essential in order to see the
neurotoxic effect of gp120 (Lipton 1992c). Unlike neurons,
macrophages express CD4 receptors that recognize gp120.
In addition, stimulation of macrophages with gp120 releases
arachidonic acid which impairs glutamate uptake by astro-
cytes (Dreyer and Lipton 1995) thus providing an explana-
tion for the build-up of glutamate in the synapse.
Tat neurotoxicity and glutamate
HIV-1 Tat is a small basic protein (86–101 residues,
depending on the viral isolate) encoded by the HIV-1 ge-
nome that plays an important role enhancing the efficiency
of transcription from viral dsDNA (Debaisieux et al. 2012).
Tat protein is encoded by two exons, the first one corre-
sponds to the 72 N-terminal residues and the second one the
remaining 14–32 residues (Cheng et al. 1998).
In addition to its role in viral replication, this protein is
secreted from intact HIV-1 infected cells at nanomolar levels
and is found in serum, CSF and brain of HIV-1 infected-
patients (Xiao et al. 2000). Fragments of Tat have been
shown to cause apoptosis in human peripheral blood mono-
nuclear cells, T-cells, neuroblastoma, rat cortical neurons
and human fetal primary neuronal cells (New et al. 1998).
Moreover, injection of HIV-1 Tat in mice caused neurotox-
icity, seizures, death, neuronal degeneration, astrocytosis
and microglia activation (Sabatier et al. 1991; Philippon et
al. 1994).
Tat peptides were shown to be neuroexcitatory and neu-
rotoxic in cultured human fetal neurons triggering the re-
lease of calcium ion from intracellular stores (Haughey et al.
1999, 2001; Holden et al. 1999). This calcium release
causes membrane depolarization, activation of metabolic
pathways, ROS generation and apoptosis (Nath et al.
1996; Kaul et al. 2001). Release of Tat-mediated calcium
ion seems dependent on NMDA receptor activation since
NMDA receptor antagonists MK-801 and D-2-amino-5-
phosphonovalerate (AP-5), significantly decrease cell death
induced in neurons and astrocytes by Tat (Eugenin et al.
2007). It is thought that Tat causes the release of Zn2+ from
its binding site on the NMDA receptor, causing activation
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and increasing its capacity to allow calcium ion influx
(Chandra et al. 2005). Tat can bind to lipoprotein related
protein (LRP) receptor and form a complex with postsynap-
tic density protein-95 (PSD-95), NMDA receptor and neu-
ronal nitric oxide synthase (nNOS) at the cell membrane in
neurons (Eugenin et al. 2007). By a mechanism not fully
understood this complex can cause apoptosis in both
NMDA receptor positive and negative neurons.
Although most studies implicate NMDA receptors, some
evidence suggests that the toxic effects of the Tat protein are
mediated through non-NMDA receptors. In fetal neurons
the non-NMDA receptor antagonists kynurenate, CNQX
and NBQX significantly decreased Tat-induced cell death
while there was no significant effect of MK-801 or AP5
(Nath et al. 1996; Cheng et al. 1998).
Tat has also been reported to cause an increase in expres-
sion levels and activity of xCT in rat primary microglia
resulting in increased glutamate release (Gupta et al. 2010).
Also, Tat decreases the expression of manganese superoxide
dismutase, which could lead to lower capacity for anti-oxidant
response in cells and ultimately induce oxidative stress (Flores
et al. 1993).
Finally, Tat seems to have synergistic effects on other
toxins like glutamate and HIV-1 gp120 causing a sig-
nificant increase in their neurotoxic potency (Wang et
al. 1999; Nath et al. 2000). Brief exposure of hippo-
campal neurons in neonatal rats to Tat and physiological
levels of NMDA caused marked cell loss supporting the
idea that locally released Tat could enhance NMDA
receptor activation-dependent neurotoxic effects (Wang
et al. 1999).
Accessory and regulatory HIV proteins neurotoxicity
and glutamate
In addition to gp120 and Tat, other less well studied HIV
proteins have been identified and have been shown to con-
tribute to glutamate-related toxicity. These include gp160,
gp41 and viral protein R (Vpr) (Hussain et al. 2008;
Gorantla et al. 2012). Gp41 facilitates the release of gluta-
mate from glial cells in vitro suggesting that this protein
may contribute to the excitotoxic effects of HIV infection
(Kort 1998). Gp41 was shown to be more effective than
gp120 at releasing glutamate in rat parietal cortical slices
(Wang and White 2000). Another study showed that both
gp120 and its precursor gp160, can both alter NMDA-
induced intracellular free calcium levels leading to neuro-
toxicity (Lannuzel et al. 1995). Vpr transgenic mice
displayed higher levels of glutamate in the cortex and basal
ganglia along with lower levels of glutamate transporters,
EAAT1 and EAAT2 (Noorbakhsh et al. 2010; Power et al.
2012). These findings correlated to disturbances in both
motor and cognitive behaviors (Noorbakhsh et al. 2010).
Regulation of glutamate excitotoxicity in HAND
Reduction of glutamate receptor signaling
Since the main toxic effects of excess glutamate are
thought to be due to excitotoxicity from over activation
of glutamate receptors, antagonists of these receptors
have been popular therapeutic targets for treatment of
HAND (Fig. 2). Early work to ameliorate the effects of
excess extracellular glutamate focused on NMDA recep-
tor antagonism, in particular with the use of 1-amino-3,
5-dimethyl-adamantane (memantine) (Lipton 2004).
Memantine is an uncompetitive low affinity antagonist
of the NMDA receptor that is approved to treat the
symptoms of Alzheimer’s disease. Memantine can block
excessive glutamate activity without interfering with the
normal functioning of the receptor (Lipton 2004). Pre-
clinical research mainly focused on the effect of
memantine on gp120 induced neuronal damage.
Memantine can prevent gp120 toxicity (Lipton 1992b;
Muller et al. 1992; Muller et al. 1996) as well as the
combined toxicity of gp120 and Tat in neuronal cultures
(Nath et al. 2000).
The first in vivo evidence of memantine’s neuroprotective
effects was established in the gp120 transgenic mice with a
significant enhancement of dendritic and presynaptic terminal
densities after treatment (Toggas et al. 1996). Impaired syn-
aptic transmission and long-term potentiation (LTP) have been
reported in SCID mice injected with human macrophages
infected with HIV-1 (Anderson et al. 2004). In this same
study, memantine was shown to attenuate these deficits. Based
on this preclinical evidence, a 20-week, randomized, double-
blind, placebo-controlled trial involving HIV-infected partici-
pants with mild to severe cognitive impairment was carried
out. Memantine showed good tolerability but no improvement
in cognitive deficits; a longer follow-up is underway (Schifitto
et al. 2007; Zhao et al. 2010).
Other NMDA receptor antagonists such as MK-801, AP-5
and 7-chloro kynurenic acid have also been shown to prevent
gp120 induced neurotoxicity in vitro (Lipton et al. 1991;
Lipton 1992a, b, c; Corasaniti et al. 1995). In contrast, the
non-NMDA receptor antagonist, CNQX failed to show any
protection (Lipton et al. 1991; Corasaniti et al. 1995). In a
recent study in rat hippocampal neurons, several NMDA
receptor antagonists were screened for their effectiveness to
prevent Tat-induced cell death and synapse loss. MK-801,
memantine and ifenprodil but not the GluN2A-selective
NMDA receptor antagonist TCN201 were neuroprotective.
Memantine and ifenprodil protected against Tat-induced cell
death but had no effect on synapse loss.MK-801 and TCN201
had the opposite effects (Shin et al. 2012). In general, howev-
er, the use of glutamate receptor antagonists in patients has
been fraught with side effects and few potent glutamate
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receptor antagonists have made it through advanced clinical
trials.
Inhibition of enzymes responsible for the formation
of glutamate
Given the side effects observed in the clinic while
trying to block postsynaptic glutamate receptors directly,
one alternative is to try to reduce the presynaptic gen-
eration and release of glutamate. In this regard, two
enzymes thought to contribute to increased levels of
glutamate in the synapse are glutamate carboxypeptidase
II (GCPII) and glutaminase. Inhibition of these two
enzymes could help abrogate the effects of glutamate
excitotoxicity (Fig. 2).
GCPII is a membrane-bound glial enzyme that catalyzes
the hydrolysis of N-acetyl-aspartyl-glutamate (NAAG) to
N-acetyl aspartate (NAA) and glutamate. NAAG is an abun-
dant peptide neurotransmitter in mammalian brain that is
thought to act as an agonist at group II metabotropic gluta-
mate receptors and a mixed agonist at the NMDA receptor
(Westbrook et al. 1986; Neale et al. 2000) , although some
controversy exists regarding these activities (Fricker et al.
2009). GCPII-catalyzed hydrolysis of NAAG is believed to
function both to terminate NAAG mediated neurotransmis-
sion and to liberate glutamate which then acts at various
glutamate receptors. Consequently, GCPII inhibitors could
help lower glutamate concentration at the synapse and alle-
viate glutamate excitotoxicity. This hypothesis has been
substantiated by numerous reports where GCPII inhibi-
tors have shown to increase extracellular NAAG and
decrease glutamate in the brain measured by microdial-
ysis (Slusher et al. 1999; Nagel et al. 2006) and provide
neuroprotective activity in over twenty animal models of
disease (Barinka et al. 2012) including inflammatory
and neuropathic pain (Chen et al. 2002; Carpenter et
al. 2003; Yamamoto et al. 2004), brain ischemia
(Slusher et al. 1999), motor neuron disease (Ghadge et
al. 2003), spinal cord and traumatic brain injury (Long
et al. 2005; Zhong et al. 2005), peripheral neuropathy
(Zhang et al. 2006; Carozzi et al. 2009), epilepsy
(Witkin et al. 2002) and drug abuse (Peng et al. 2010;
Xi et al. 2010). Further, a GCPII inhibitor, 2-MPPA
(2-(3-mercaptopropyl) pentanedioic acid), was used in
humans in an exploratory study to assess safety and
tolerability of GCPII inhibition. 2-MPPA did not pro-
voke any adverse CNS effects and was well tolerated
(van der Post et al. 2005).
The potential therapeutic utility of GCPII inhibition in
AIDS-related neurotoxicity was recently evaluated in an in
vitro model using rat embryonic hippocampal cultures and
gp120IIIB. Gp120IIIB exhibits specificity for CXCR4, the
receptor known to induce neuronal apoptosis. 2-PMPA, a
potent and selective GCPII inhibitor (Jackson et al. 1996)
prevented gp120III-induced apoptosis in a dose-dependent
manner. Apoptosis could be resumed in the presence of
mGlu3 receptor antagonists or in the presence of antibodies
to transforming growth factor (TGF)-β. The results suggest
neuroprotection can be mediated through increases in
NAAG and subsequent action at the mGlu3 receptors and
TGF-β release. Consistent with the localization of GCPII in
astrocytic cells, 2-PMPA failed to provide neuroprotection
in the absence of glia (Thomas et al. 2009). Evaluation of
GCPII inhibitors in animal models of HAND is underway.
Glutaminase catalyzes the hydrolysis of glutamine to
glutamate and it is thought to be a major source of glutamate
production in the CNS. HIV-1 infected human macrophages
and human primary fetal microglia have increased glutamin-
ase mRNA and protein levels (Tian et al. 2008; Erdmann et
al. 2009; Huang et al. 2011; Zhao et al. 2012). Macrophages
infected with various HIV-1 strains were reported to release
high levels of glutamate in the presence of glutamine and
this release was inhibited by glutaminase siRNA as well as
several structurally diverse glutaminase inhibitors including
6-diazo-5-oxo-L-norleucine (DON), BPTES and its analogs
(Zhao et al. 2004; Erdmann et al. 2007). Additional mech-
anistic studies of glutamate generation in HIV-1 infected
macrophages revealed up-regulation of the glutaminase iso-
form GAC. Glutaminase is normally found in mitochondria
but upon infection it is released into cytosol and extracellu-
lar space where high levels of glutamine could be rapidly
converted to glutamate (Erdmann et al. 2009). Unfortunate-
ly, current prototype glutaminase inhibitors are non-specific
and reactive (Zhao et al. 2004) or exhibit poor solubility
(Wang et al. 2010; Hartwick and Curthoys 2011). Conse-
quently, a meaningful evaluation of the potential of gluta-
minase inhibition to prevent glutamate excitotoxicity in
animal models of neuroAIDS awaits the identification of
better drug-like glutaminase inhibitors
Regulation of glutamate transporters
Oxidative stress in macrophages and microglia is also
thought to contribute to increased extracellular glutamate
through xCT. Treatment of macrophages and microglial
cells with pro-inflammatory factors like lipopolysaccharides
(LPS) or HIV-1 Tat protein causes lipid peroxidation due to
the ROS that are generated. Cells affected by oxidative
stress show alterations in cell signaling, membrane organi-
zation, and protein and DNA modification (Niki 2009). In
order to neutralize lipid peroxidation, glutathione-S-
transferase (GST) catalyzes reactions between reduced glu-
tathione (GSH) and oxidized lipids to form products like 4-
hydroxynonenal (4-HNE) and acrolein. This detoxification
process irreversibly consumes the GSH available in the cell
decreasing the anti-oxidant protective power. Replenishment
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of intracellular GSH is thought to occur through xCT which
shuttles cystine (cys2) inside the cell in exchange for gluta-
mate that is released from the cell. Cys2 is the main source
of cysteine, required for GSH synthesis. This enhanced
cys2 uptake to replenish GSH causes an increase in
extracellular glutamate that in turn can contribute to
neurotoxicity (Barger et al. 2007). The antiporter also
supports a redox cycle over the plasma membrane
where cys2 uptake is followed by intracellular reduction
to cysteine and secretion of surplus cysteine into the
extracellular space (Banjac et al. 2008; Conrad and Sato
2011). Overall, xCT appears to support an endogenous
antioxidant response (through the uptake of cys2 as well
as the release of cysteine) with the concomitant increase
of extracellular glutamate. However, the antioxidant re-
sponse can become neurotoxic when it is activated
during inflammation associated with neurodegeneration.
When macrophages are stimulated by LPS or TNFα,
they import cys2 and release cysteine into the medium
resulting in a reduced milieu conducive to T cell acti-
vation; the accumulation of extracellular thiols is
inhibited by glutamate suggesting the involvement of
xCT (Angelini et al. 2002). Exposure of cultured pri-
mary microglia to HIV Tat causes dose-dependent in-
creases in extracellular glutamate; these increases
become higher in the presence of morphine in accor-
dance with the immunomodulatory properties of this
opiate agonist. Tat-induced glutamate release was asso-
ciated with increased expression of the xCT antiporter
and was inhibited by the xCT prototype inhibitors DL-
aminoadipic acid and 4-carboxyphenylglycine (Gupta et
al. 2010). These findings suggest that Tat-mediated ac-
tivation of xCT could be playing a role in HIV-related
pathology and that xCT inhibitors have potential for the
treatment of HAND.
HIV-mediated neurotoxicity can also result in inhibition
of glutamate transporters GLT1, GLAST, and EAAC1
(Trotti et al. 1996) or in reduction of their expression
(Noorbakhsh et al. 2010; Power et al. 2012). Since these
transporters are involved in the reuptake of glutamate by the
cell after glutamate neurotransmission, inhibition or reduc-
tion of expression of these transporters results in aberrant
activation of glutamate receptors (Sheldon and Robinson
2007). Consequently, one potential approach is to search
for transport activators that could increase either their activ-
ity or their expression. This approach has shown promise
in other glutamate –related disorders such as ALS
(Rothstein et al. 2005). Recent work reports on the
identification of pyridazine derivatives that increase the
protein levels of the glutamate transporter EAAT2 in
astrocytes. (Xing et al. 2011). The effect of these acti-
vators in models of neurodegenerative disease including
HAND awaits investigation.
Animal models to investigate effects of glutamate
regulation in HAND
In order to investigate if glutamatergic-based therapeutics
can be effective in eliminating the symptoms of HAND, one
needs an appropriate preclinical animal model. The genera-
tion of animal models of HIV has proven to be very chal-
lenging owing to the fact that HIV itself is not infectious to
rodents. In order to create an accurate animal model for
HAND several criteria need to be met. The animal model
needs to possess target CNS cells that are permissive to
virus infection, have a chronic infection period, display
altered blood–brain barrier function to permit transmigration
of infected cells and have the ability to maintain viral
reservoirs (Gorantla et al. 2012). It would also need to
feature the generation of viral proteins such as Tat and
gp120 as well as the release of neurotoxic products such
as proinflammatory cytokines, chemokines, quinolinic acid,
glutamate, arachidonic acid and nitric acid among others.
Since the discovery of HIV, several animal models of
HAND have been created (Table 1), but like many models
of neurodegenerative diseases, no one current model reca-
pitulates the exact characteristics of HAND or HIV-1 asso-
ciated dementia (HAD) (Gorantla et al. 2012; Jaeger and
Nath 2012).
Some of the first and most logical models to be generated
were where the full-length HIV-1 DNAwas inserted into the
mouse genome under the control of various promoters
(Santoro et al. 1994; Thomas et al. 1994; Gorantla et al.
2012). A HIV-1 transgenic rat was also developed and
cognitive deficits such as impairments in spatial learning
as well as evidence of other clinical manifestations of the
disease have been reported making it a suitable model for
testing therapeutics in rats (Reid et al. 2001; Vigorito et al.
2007; Lashomb et al. 2009). The most commonly used
mouse models for HIV are those that express some of the
viral proteins generated upon HIV infection such as Tat and
gp120 (Toggas et al. 1994; Kim et al. 2003; Gorantla et al.
2012). GFAP-Tat Tg mice possess doxycycline-inducible
expression of the Tat protein under control of GFAP pro-
moter while GFAP-HIVgp-120 Tg mice exhibit expression
of gp120 protein driven by GFAP promoter that is not
inducible (Toggas et al. 1994; Kim et al. 2003; Bruce-
Keller et al. 2008). Spatial learning on the Morris water
maze was shown to be impaired in the gp-120 mice
(D’Hooge et al. 1999). This is thought to be due to
excitotoxic mechanisms as a result of increased NMDA
receptor signaling and impaired hippocampal long-term po-
tentiation (LTP) which is believed to be the NMDA
receptor-dependent biological correlate of learning and
memory (Lipton 1994; Toggas et al. 1996). Indeed, as
mentioned previously, the first in vivo evidence of the
NMDA receptor antagonist, memantine’s neuroprotective
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effects was established in these gp120 transgenic mice
(Toggas et al. 1996). Like the gp120 mice, the Tat transgenic
mice also exhibit memory deficits as demonstrated by di-
minished performance in hippocampal-dependent memory
tasks such as the Barnes maze, Morris water maze, fear
conditioning and novel object recognition (Carey et al.
2012; Fitting et al. 2012). Interestingly, Tat transgenic mice
display an increase in expression of the xCT antiporter
which could be the response to increased oxidative stress
and excitotoxicity (Bridges et al. 2004). Like gp-120, the Tat
protein has been shown to interfere with LTP (Li et al. 2004;
Fitting et al. 2012). Since the gp120 and Tat proteins both
induce impairments to the glutamate system, these models
can be appropriately used to test glutamatergic therapeutics.
Direct injection of these proteins into brain areas has also
been used to model HAND and have shown cognitive and
sensorimotor gating impairments as well as interference in
LTP (Glowa et al. 1992; Pugh et al. 2000; Sanchez-Alavez
et al. 2000; Li et al. 2004; Fitting et al. 2006; Fernandes et
al. 2007). As mentioned above, injection of HIV-1 Tat in
mice caused neurotoxicity, seizures, death, neuronal degener-
ation, astrocytosis and microglia activation (Sabatier et al.
1991; Philippon et al. 1994). Future generation of double or
triple transgenic lines combined with the introduction of some
neurotoxic products or supernatants from HIV-infected mac-
rophages might be needed to convey the collective effects of
the various viral proteins and other HIV-generated toxins in
the CNS.
To overcome the fact that HIV does not infect mice, two
approaches were undertaken to circumvent the restriction of
HIV-1 entry to rodent species. The first approach was on the
host side with the generation of various types of humanized
mouse models that incorporated a functional human im-
mune system (HIS) into severe combined immunodeficient
(SCID) mice and thus permitting HIV infection (Jaeger and
Nath 2012). HIV-1 infected monocyte derived macrophages
(MDM) were also injected into these SCID mice to create
HIVencephalitic (HIVE) mice and many of the pathological
features of HIVE as well as cognitive and plasticity deficits
were reproduced in these mice which were attenuated with
memantine (Tyor et al. 1993; Avgeropoulos et al. 1998;
Zink et al. 2002; Anderson et al. 2004; Sas et al. 2007).
These mice have been widely used for therapeutic testing
but biosafety requirements make them difficult to work with
(Gorantla et al. 2012). The other approach to overcome the
issue of species recognition was on the side of the virus
Table 1 Rodent models of HAND
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itself. This was accomplished by replacing the coding region
of HIV-1 gp120 with that of gp80 from a rodent-infectious
retrovirus called ectotropic murine leukemia virus resulting
in the EcoHIV construct (Potash et al. 2005). Cognitive
testing has not been carried out in these mice nor have any
defects in LTP or the glutamate system been reported to
date. These mice have been successfully used for the pre-
clinical evaluation of antiretroviral drugs and vaccines
(Hadas et al. 2007; Saini et al. 2007).
All of these models have potential to be used to evaluate
new therapeutics but each have their individual pros and
cons and none of them encompass the entire HAND symp-
tom repertoire. It is clear that the glutamate system is affect-
ed following HIV infection of the CNS and therapeutics
aimed at ameliorating these deficits may be beneficial for
the symptoms of HAND.
In summary, glutamate excitotoxicity is one of several
mechanisms by which HIV exerts neurotoxicity that culmi-
nates in HAND. Glutamate is released upon HIV infection
of macrophage/microglial cells and has been associated with
neurotoxicity mediated by gp120, Tat and other HIV pro-
teins. Several strategies have been used over the years to try
to prevent glutamate excitotoxicity, including direct block-
ade of glutamate receptors. Unfortunately, this approach is
fraught with side effects. Another approach has been to
inhibit enzymes responsible for the production of glutamate
such as glutaminase and GCPII or to regulate the trans-
porters responsible for modulation of extracellular gluta-
mate such as EAAT and xCT. These efforts however, are
at an early stage where next steps are dependent on the
identification of drug-like inhibitors as well as the develop-
ment of predictive neuroAIDS animal models.
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